Suvorexant for Treatment of AUD and PTSD
NCT06679062
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)
- Insomnia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- The University of Texas Health Science Center - Houston · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.